AstraZeneca (AZN) Reports Q4 EPS of $1.30

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.30, $0.83 better than the analyst estimate of $0.47. Revenue for the quarter came in at $5.78 billion versus the consensus estimate of $5.45 billion.

GUIDANCE:

AstraZeneca sees FY2018 EPS of $3.30-$3.50, versus the consensus of $1.62.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance